127168-73-4

Basic information

• Product Name: 4-METHOXYISOINDOLINE
• Synonyms: 4-METHOXYISOINDOLINE;4-Methoxy-2,3-dihydro-1H-isoindole
• CAS NO: 127168-73-4
• Molecular Formula: C₉H₁₁NO
• Molecular Weight: 149.19
• Mol File: 127168-73-4.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 265.1 °C at 760 mmHg
• Flash Point: 99.4 °C
• Appearance: /
• Density: 1.076 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 4-METHOXYISOINDOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHOXYISOINDOLINE(127168-73-4)
• EPA Substance Registry System: 4-METHOXYISOINDOLINE(127168-73-4)

Safety Data

• Hazardous Substances Data: 127168-73-4(Hazardous Substances Data)

Usage

General Description

4-Methoxyisoindoline, also known as 1-Methoxyisoindoline, is an organic compound that belongs to the class of isoindolines. It is a colorless to pale yellow liquid with a fruity odor. This chemical is used as an intermediate in the synthesis of various pharmaceuticals, agrochemicals, and other organic compounds. Its unique structure and reactivity make it a valuable building block in the production of diverse products. Additionally, 4-Methoxyisoindoline exhibits potential pharmacological properties and has been studied for its potential therapeutic applications in the treatment of various diseases. Overall, it is a versatile compound with a wide range of industrial, pharmaceutical, and research applications.

Upstream product

• 71785-96-1 2,3-bisbromomethylanisole 
• 2944-49-2 2,3-dimethylanisole 
• 871013-92-2 tert-butyl 4-hydroxy-1,3-dihydro-2H-isoindole-2-carboxylate 
• 1035235-27-8 tert-butyl 4-bromo-2,3-dihydro-1H-isoindole-2-carboxylate 
• 1035235-28-9 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindoline-2-carboxylic acid tert-butyl ester 
• 41709-83-5 4-methoxy-isoindole-1,3-dione 

Downstream Products

• 508237-25-0 5-(3,4-Dimethoxybenzylamino)-2-(2-furyl)-8-(4-methoxyisoindolin-2-ylmethyl)[1,2,4]triazolo[1,5-c]pyrimidine 

Relevant articles and documents

As neuroprotective agents of pharmaceutical compounds

The invention discloses a medicinal compound as a neuroprotective agent. The medicinal compound is a neuronal nitric oxide synthase-postsynaptic density protein 95 (nNOS-PSD95) decoupling agent. The medicinal compound is a benzene ring derivative shown in the general formula (I) or its pharmaceutically acceptable salt. The invention further discloses a preparation method of the medicinal compound and a use of the medicinal compound in prevention and treatment on neuronal damage influence-caused diseases.

RHO KINASE INHIBITORS

The invention provides novel inhibitors of ROCK1 and/or ROCK2. Also provided are methods of treating diseases and disorders involving inhibiting ROCK1 and/or ROCK2. The present invention includes pharmaceutical compositions comprising the compounds of the invention and a pharmaceutically acceptable carrier and/or diluents. The present invention includes compositions comprising a substantially pure compound of the invention and a pharmaceutically acceptable salt, steroisomer, or hydrate thereof: and a pharmaceutically acceptable excipient and/or diluents.

PHARMACEUTICAL COMBINATIONS

The invention provides combinations comprising (or consisting essentially of) one or more ancillary compound(s) and a compound of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein R1 is hydroxy or hydrogen; R2 is hydroxy; methoxy or hydrogen; provided that at least one of R1 and R2 is hydroxy; R3 is selected from hydrogen; halogen; cyano; optionally substituted C1-5 hydrocarbyl and optionally substituted C1- 5 hydrocarbyloxy; R4 is selected from hydrogen; a group -(O)n-R7 where n is 0 or 1 and R7 is an optionally substituted acyclic C1-5 hydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and optionally substituted mono- or di-C1-5 hydrocarbyl-amino; or R3 and R4 together form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and NR5R6 forms an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 ring members are heteroatoms selected from oxygen, nitrogen and sulphur. The combinations have activity as Hsp90 inhibitors.